Clinical Trial Update: Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing immune checkpoint therapy with targeted therapy to reduce HBsAg levels in patients with HBsAg-positive advanced hepatocellular carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Humanity & Health Medical Group Limited | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING